AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02644915
Drug: Edaravone
RxNorm normalized name: Edaravone
DrugBank: Edaravone (DB12243)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Edaravone 30mg dissolved in 0.9%NaCl 100ml will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.The number of dialysis and the serum creatinine level within the first week after the transplantation will be recorded.The participation of each patient is scheduled for 1 month.
Trial: NCT00003405
Drug: amifostine trihydrate
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003405
Drug: bromodeoxyuridine
RxNorm normalized name: Bromodeoxyuridine
DrugBank: Broxuridine (DB12028)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003405
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003405
Drug: idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003405
Drug: idoxuridine
RxNorm normalized name: Idoxuridine
DrugBank: Idoxuridine (DB00249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003405
Drug: isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003405
Drug: mitoxantrone hydrochloride
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01654692
Drug: Ipilimumab and Fotemustine
RxNorm normalized name: Ipilimumab
DrugBank: Fotemustine (DB04106)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab: 10 mg/kg q3 weeks for 4 doses, q12 weeks starting at Week 24 Fotemustine: 100 mg/m2 q1 week for 3 doses, q3 weeks starting at Week 9
Trial: NCT00619723
Drug: Citicoline
RxNorm normalized name: Citicoline
DrugBank: Citicoline (DB12153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline is a psychostimulant/nootropic. It is an intermediate in the generation of phosphatidylcholine from choline.
Trial: NCT01184495
Drug: Epoetin Alfa-BioManguinhos
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of EPO-BioManguinhos
Trial: NCT01184495
Drug: Epoetin Alfa-BioSimilar
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of EPO-BioSimilar
Trial: NCT01313377
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01313377
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03644186
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy plus HER2 Blockade
Trial: NCT02390947
Drug: Famitinib
RxNorm normalized name: Famitinib
DrugBank: Famitinib (DB11741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg p.o. qd
Trial: NCT01541085
Drug: Darunavir/Ritonavir (DRV/r)
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darunavir/Ritonavir (DRV/r) + Tenofovir/Emtricitabina regimen
Trial: NCT01541085
Drug: Efavirenz (EFV)
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz (EFV) + Tenofovir/Emtricitabina regimen
Trial: NCT04678050
Drug: Ketamine/ propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketamine/propofol mixture, each mL contains 5 mg of ketamine plus 10 mg of propofol). A loading dose of 0.125 mL/kg will be administered intravenously (IV) over 10 min, followed by maintenance infusion at a rate of 0.05-0.125 mL/kg/h.
Trial: NCT04678050
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dex solution (4 µg/mL). A loading dose of 2 µg/kg will be administered IV over 10 min, followed by a maintenance infusion of 0.1-1 µg/kg/h
Trial: NCT05099250
Drug: Bupivacain
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local anesthetic agent
Trial: NCT05099250
Drug: magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In the central nervous system , it has depressant effects, by antagonism at NMDA receptors and through inhibition of release of catecholamines
Trial: NCT02666443
Drug: Control intervention (no dexamethasone)
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 50 mL normal saline.
Trial: NCT02666443
Drug: Peri-neural Dexamethasone 1 mg
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL dexamethasone 1% (1 mg dexamethasone), and an intravenous solution of 50 mL normal saline.
Trial: NCT02666443
Drug: Intravenous Dexamethasone 1 mg
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 49.9 mL normal saline with 0.1mL dexamethasone 1%
Trial: NCT03644186
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy plus HER2 Blockade
Trial: NCT03644186
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy plus HER2 Blockade
Trial: NCT03644186
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
Trial: NCT03644186
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
Trial: NCT03644186
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
Trial: NCT03644186
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
Trial: NCT03853109
Drug: AMG 404
RxNorm normalized name: Anti-pd-1 monoclonal antibody amg 404
DrugBank: AMG 424 (DB17357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 404 will be examined for safety, tolerability, PK, and PD of AMG 404 in subjects with advanced solid tumors.
Trial: NCT04310995
Drug: Nicorandil 5mg tid
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral Nicorandil Tablets 5mg (5mg per tablet) three times daily for 24 weeks
Trial: NCT04310995
Drug: Diltiazem 180mg qd
RxNorm normalized name: diltiazem hydrochloride 180 MG
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral Diltiazem Sustained-release Tables180mg (90 mg per tablet) once daily for 24 weeks
Trial: NCT04310995
Drug: Isosorbide Mononitrate 50mg qd
RxNorm normalized name: isosorbide mononitrate 50 MG
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral Isosorbide Mononitrate Sustained-release Capsules 50 mg (50mg per capsule) once daily for 24 weeks
Trial: NCT03888066
Drug: Patiromer
RxNorm normalized name: Patiromer
DrugBank: Patiromer (DB09263)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose of patiromer will be 1 packet/day and may be taken either with food or without food. Based upon the patiromer treatment algorithm patiromer may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, patiromer may be decreased to a minimum of 0 packets/day. Doses of patiromer will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).
Trial: NCT03857646
Drug: Soybean oil Medium-chain triglycerides Olive oil Fish Oil (SMOF) lipid
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipids start at 1 g/kg/day and advance by 1 g/kg/day to a maximum of 3 g/kg/day as tolerated by the the neonate.
Trial: NCT00168935
Drug: Fresubin protein energy Drink (CAVE! nutritional intervention)
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01860235
Drug: EMLA
RxNorm normalized name: EMLA
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: % eutectic mixture of 25mg/g lidocaine and 25 mg/g of prilocaine
Trial: NCT01435083
Drug: Desmopressin
RxNorm normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 120 µg, oral lyophilisate, sublingual use
Trial: NCT01722968
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly
Trial: NCT01722968
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80mg/m2 iv weekly
Trial: NCT04518878
Drug: Eltrombopag
RxNorm normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fixed dose of eltrombopag oral 25mg daily
Trial: NCT04518878
Drug: rhTPO
RxNorm normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rh-TPO 300U/kg subcutaneous injection once daily for 7 consecutive days, followed by a tapering dose in maintenance therapy.
Trial: NCT00030719
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00030719
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00030719
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00030719
Drug: isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00030719
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00030719
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03422874
Drug: Nelfinavir
RxNorm normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nelfinavir is an oral HIV protease inhibitor approved by FDA in 1997, now available in generic form. It has a well established safety profile in HIV patients when administered at the recommended dose of 1250 mg PO BID. Nelfinavir was shown to induce ER stress in cancer cell lines and xenograft tumors leading to apoptosis and tumor growth inhibition.
Trial: NCT00456638
Drug: Depodur
RxNorm normalized name: Depodur
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Depodur vs. traditional management
Trial: NCT01386528
Drug: nonacog beta pegol
RxNorm normalized name: Nonacog beta pegol
DrugBank: Nonacog beta pegol (DB13933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive nonacog beta pegol at screening just prior to and during surgical intervention, administered intravenously (into the vein).
Trial: NCT01559298
Drug: Aspirin (80 mg/d) + clopidogrel (75 mg/d)
RxNorm normalized name: D
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Aspirin (80 mg/d) + clopidogrel (75 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months. Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months. Patients will be followed either by phone contact or clinical visits at 1- and 12-month follow-up.
Trial: NCT01559298
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (80 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
Trial: NCT00785655
Drug: Dermacyd PH_DETINLYN (Lactic Acid)
RxNorm normalized name: PH-284
DrugBank: PH-284 (DB05452)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03516448
Drug: Tyroserleutide for injection
RxNorm normalized name: Tyroserleutide
DrugBank: Tyroserleutide (DB17300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6mg/d, 5days,ivgtt
Trial: NCT02856555
Drug: Firsocostat
RxNorm normalized name: Firsocostat
DrugBank: Firsocostat (DB16166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules orally once daily.
Trial: NCT02340481
Drug: Loperamide hydrochloride + simethicone chewable tablet
RxNorm normalized name: loperamide hydrochloride / simethicone Chewable Tablet
DrugBank: Loperamide (DB00836)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each tablet contains 2 milligram (mg) of loperamide hydrochloride and 125 mg of simethicone.
Trial: NCT02340481
Drug: Loperamide hydrochloride
RxNorm normalized name: Loperamide Hydrochloride
DrugBank: Loperamide (DB00836)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each capsule contains 2 mg of loperamide hydrochloride
Trial: NCT02340481
Drug: Loperamide hydrochloride + simethicone chewable placebo tablet
RxNorm normalized name: loperamide hydrochloride / simethicone Chewable Tablet
DrugBank: Loperamide (DB00836)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo matched to loperamide hydrochloride and simethicone chewable tablet.
Trial: NCT02340481
Drug: Loperamide hydrochloride placebo capsule
RxNorm normalized name: Loperamide Hydrochloride
DrugBank: Loperamide (DB00836)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo matched to loperamide hydrochloride capsule.
Trial: NCT00005603
Drug: asparaginase
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005603
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005603
Drug: daunorubicin hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005603
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005603
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005603
Drug: thioguanine
RxNorm normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005603
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03196843
Drug: Raltitrexed
RxNorm normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltitrexed 2.5mg/m2 on day 1,22,43 during radiotherapy
Trial: NCT01391715
Drug: rabeprazole
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rabeprazole 20mg bid per day for 2 weeks
Trial: NCT01391715
Drug: standard dose rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rabeprazole 20mg qd per day for 2 weeks
Trial: NCT01437488
Drug: Cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Cycle 1: 20 mg/m2 in 250cc NS via IV on Day 1 every 21 days~* Following cycles: 20 mg/m2 or escalated to 25 mg/m2 or reduced by 5 mg/m2 in 250cc NS via IV on Day 1 every 21 days at investigator's discretion~* Treatment continues until disease progression, intercurrent illness preventing further treatment, unacceptable adverse event(s), patient withdraws from the study, or changes in the patient's condition which render further treatment unacceptable in the judgment of the investigator
Trial: NCT01437488
Drug: Neulasta
RxNorm normalized name: Neulasta
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 6 mg via SQ on Day 2 (24-48 hours post-cabazitaxel) every 21 days
Trial: NCT00573261
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will take pregabalin for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
Trial: NCT02872428
Drug: Valproic Acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: By infusion over 1 hour
Trial: NCT02187991
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: either 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel plus Alisertib arm) or 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel Alone arm)
Trial: NCT02187991
Drug: Alisertib
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg BID (twice a day) on days 1-3, 8-10, and 15-17 of a 28-day cycle
Trial: NCT00649194
Drug: Rabeprazole Sodium Delayed-Release Tablets 20 mg
RxNorm normalized name: rabeprazole sodium Delayed Release Oral Tablet
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg, single dose fed
Trial: NCT00290641
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00290641
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00290641
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01531517
Drug: Royal Jelly and Panthenol (PedyPhar® Ointment)
RxNorm normalized name: ROYAL JELLY
DrugBank: Panthenol (DB11204)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the following will be done to each patient depending on the number of the visit:~1. Assessment of the patient for inclusion/exclusion criteria~2. Informed consent process~3. Medical history of the patient~4. Blood withdrawn for investigation~5. Drainage of the ulcer if there is a collection~6. Revascularization as needed and indicated by APSV done at visit 0.~7. Swab from the ulcer for culture and micro-organism count: on detailed visits only.~8. Debridement as needed.~9. Dressing:~   * Inspection and assessment of the ulcer~  * Irrigation using 500 ml of saline or as required.~  * Drying of the ulcer (leave to dry)~  * Spread a layer of 3 - 5 mm of PedyPhar on a dressing and then apply the dressing to the ulcer~  * Fix the dressing to the ulcer
Trial: NCT01531517
Drug: Panthenol Ointment
RxNorm normalized name: Panthenol
DrugBank: Panthenol (DB11204)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the following will be done to each patient depending on the number of the visit:~1. Assessment of the patient for inclusion/exclusion criteria~2. Informed consent process~3. Medical history of the patient~4. Blood withdrawn for investigation~5. Drainage of the ulcer if there is a collection~6. Revascularization as needed and indicated by APSV done at visit 0.~7. Swab from the ulcer for culture and micro-organism count: on detailed visits only.~8. Debridement as needed.~9. Dressing:~   * Inspection and assessment of the ulcer~  * Irrigation using 500 ml of saline or as required.~  * Drying of the ulcer (leave to dry)~  * Spread a layer of 3 - 5 mm of Panthenol on a dressing and then apply the dressing to the ulcer~  * Fix the dressing to the ulcer
Trial: NCT05076461
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron group received oral suspension of ondansetron as 0.15mg per body weight
Trial: NCT00001587
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03598270
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous. Day 1
Trial: NCT03598270
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 175 mg/m². Intravenous. Day 1
Trial: NCT03598270
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg or 300 mg. Oral. From day 1 to 21
Trial: NCT03598270
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m². Intravenous. Day 1 and day 8.
Trial: NCT03598270
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200 mg. Intravenous. Day 1
Trial: NCT00417079
Drug: cabazitaxel (XRP6258) (RPR116258)
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m\^2 administered by intravenous (IV) route over 1 hour on day 1 of each 21-day cycle